JP2015508104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508104A5 JP2015508104A5 JP2014558897A JP2014558897A JP2015508104A5 JP 2015508104 A5 JP2015508104 A5 JP 2015508104A5 JP 2014558897 A JP2014558897 A JP 2014558897A JP 2014558897 A JP2014558897 A JP 2014558897A JP 2015508104 A5 JP2015508104 A5 JP 2015508104A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- therapeutic agent
- silk
- silk matrix
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 145
- 239000003814 drug Substances 0.000 claims description 118
- 229940124597 therapeutic agent Drugs 0.000 claims description 116
- 239000011159 matrix material Substances 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 86
- 239000000017 hydrogel Substances 0.000 claims description 34
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 30
- 230000001225 therapeutic effect Effects 0.000 claims description 24
- 229960000397 bevacizumab Drugs 0.000 claims description 20
- 229960003876 ranibizumab Drugs 0.000 claims description 20
- 108091008605 VEGF receptors Proteins 0.000 claims description 18
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 18
- 239000007863 gel particle Substances 0.000 claims description 18
- 239000007943 implant Substances 0.000 claims description 18
- 239000011859 microparticle Substances 0.000 claims description 18
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 108010022355 Fibroins Proteins 0.000 claims description 14
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 12
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims description 12
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims description 12
- 229960002833 aflibercept Drugs 0.000 claims description 12
- 108010081667 aflibercept Proteins 0.000 claims description 12
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 12
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 12
- 229960003005 axitinib Drugs 0.000 claims description 12
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 229960003407 pegaptanib Drugs 0.000 claims description 12
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 12
- -1 poly (phosphate ester Chemical class 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 229960000940 tivozanib Drugs 0.000 claims description 12
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 12
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 12
- 239000000835 fiber Substances 0.000 claims description 10
- 229940043355 kinase inhibitor Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229920000954 Polyglycolide Polymers 0.000 claims description 8
- 229920000249 biocompatible polymer Polymers 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000004633 polyglycolic acid Substances 0.000 claims description 8
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 claims description 6
- NNPJZJJMQDXYGN-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide;hydrochloride Chemical compound Cl.S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 NNPJZJJMQDXYGN-UHFFFAOYSA-N 0.000 claims description 6
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims description 6
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 6
- 108090000644 Angiozyme Proteins 0.000 claims description 6
- 108091023037 Aptamer Proteins 0.000 claims description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 6
- 241000251730 Chondrichthyes Species 0.000 claims description 6
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 6
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 6
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 108010059993 Vancomycin Proteins 0.000 claims description 6
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 229960004821 amikacin Drugs 0.000 claims description 6
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 6
- 229960003942 amphotericin b Drugs 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 230000000711 cancerogenic effect Effects 0.000 claims description 6
- 231100000315 carcinogenic Toxicity 0.000 claims description 6
- 210000000845 cartilage Anatomy 0.000 claims description 6
- 229960002412 cediranib Drugs 0.000 claims description 6
- 229960000484 ceftazidime Drugs 0.000 claims description 6
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000010408 film Substances 0.000 claims description 6
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 6
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 6
- 229960005102 foscarnet Drugs 0.000 claims description 6
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 claims description 6
- 229960000936 fumagillin Drugs 0.000 claims description 6
- 229960002963 ganciclovir Drugs 0.000 claims description 6
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000008176 lyophilized powder Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
- 239000002924 silencing RNA Substances 0.000 claims description 6
- 239000004055 small Interfering RNA Substances 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 229960003787 sorafenib Drugs 0.000 claims description 6
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 6
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 229960003165 vancomycin Drugs 0.000 claims description 6
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 6
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims description 6
- 210000004127 vitreous body Anatomy 0.000 claims description 6
- 208000014882 Carotid artery disease Diseases 0.000 claims description 4
- 208000002691 Choroiditis Diseases 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 229920001710 Polyorthoester Polymers 0.000 claims description 4
- 208000003971 Posterior uveitis Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- 210000001742 aqueous humor Anatomy 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 230000001886 ciliary effect Effects 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 210000000795 conjunctiva Anatomy 0.000 claims description 4
- 239000000645 desinfectant Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229940099552 hyaluronan Drugs 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 239000002745 poly(ortho ester) Substances 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- 210000001525 retina Anatomy 0.000 claims description 4
- 210000001927 retinal artery Anatomy 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 4
- 210000003786 sclera Anatomy 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 229920000428 triblock copolymer Polymers 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- 210000000695 crystalline len Anatomy 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010070957 Choroidal haemangioma Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- 208000021089 Coats disease Diseases 0.000 claims description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000002927 Hamartoma Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000009857 Microaneurysm Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims description 2
- 206010038821 Retinal anomaly congenital Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000016624 Retinal neoplasm Diseases 0.000 claims description 2
- 206010038899 Retinal telangiectasia Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 208000036038 Subretinal fibrosis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 2
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 206010072959 birdshot chorioretinopathy Diseases 0.000 claims description 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000009852 coagulant defect Effects 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 2
- 201000011190 diabetic macular edema Diseases 0.000 claims description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 206010014801 endophthalmitis Diseases 0.000 claims description 2
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims description 2
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 2
- 210000002445 nipple Anatomy 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 201000004849 posterior scleritis Diseases 0.000 claims description 2
- 201000002267 posterior uveal melanoma Diseases 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 201000008933 retinal cancer Diseases 0.000 claims description 2
- 239000000790 retinal pigment Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 230000008397 ocular pathology Effects 0.000 claims 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601924P | 2012-02-22 | 2012-02-22 | |
| US61/601,924 | 2012-02-22 | ||
| PCT/US2013/027465 WO2013126799A1 (en) | 2012-02-22 | 2013-02-22 | Compositions and methods for ocular delivery of a therapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015508104A JP2015508104A (ja) | 2015-03-16 |
| JP2015508104A5 true JP2015508104A5 (https=) | 2016-04-14 |
Family
ID=49006267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558897A Pending JP2015508104A (ja) | 2012-02-22 | 2013-02-22 | 治療薬の眼への送達のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150037422A1 (https=) |
| EP (1) | EP2817031A4 (https=) |
| JP (1) | JP2015508104A (https=) |
| CA (1) | CA2865132A1 (https=) |
| HK (1) | HK1205461A1 (https=) |
| WO (1) | WO2013126799A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2916827B1 (en) * | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| CA2939952C (en) | 2013-03-05 | 2022-03-22 | Morgan V. Fedorchak | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery |
| PL2968650T3 (pl) | 2013-03-14 | 2019-05-31 | Panoptica Inc | Preparaty do oczu do dostarczania leku do tylnego fragmentu oka |
| US11376329B2 (en) | 2013-03-15 | 2022-07-05 | Trustees Of Tufts College | Low molecular weight silk compositions and stabilizing silk compositions |
| WO2014145002A2 (en) | 2013-03-15 | 2014-09-18 | Kluge Jonathan A | Low molecular weight silk compositions and stabilizing silk compositions |
| EP4137139A1 (en) | 2013-07-10 | 2023-02-22 | Matrix Biology Institute | Compositions of hyaluronan with high elasticity and uses thereof |
| US20150164882A1 (en) * | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20150129457A1 (en) * | 2013-07-22 | 2015-05-14 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| CN104667287B (zh) * | 2013-11-27 | 2018-02-06 | 山东博士伦福瑞达制药有限公司 | 用于治疗眼后房新生血管增生的眼用组合物及其用途 |
| CN103656746A (zh) * | 2013-12-13 | 2014-03-26 | 无锡合众信息科技有限公司 | 一种可自愈水凝胶玻璃体填充物及其制备方法 |
| WO2015106005A1 (en) * | 2014-01-08 | 2015-07-16 | Circuit Therapeutics, Inc. | Method for therapeutic management of ocular hypertension |
| US10010610B2 (en) * | 2014-01-16 | 2018-07-03 | Retinal Therapies, LLC | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
| WO2015117888A1 (en) * | 2014-02-04 | 2015-08-13 | Amsilk Gmbh | Coated silk films, methods for the production thereof and uses thereof |
| CN104027847B (zh) * | 2014-06-20 | 2015-08-26 | 西安交通大学 | 一种附带血管网流道的人工软组织体的制造方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2781114T3 (es) | 2014-08-20 | 2020-08-28 | Silk Tech Ltd | Composición proteica derivada de fibroína |
| ES2863601T3 (es) * | 2014-09-17 | 2021-10-11 | Panoptica Inc | Formulaciones oculares para administración de fármacos y protección del segmento anterior del ojo |
| CN104368046B (zh) * | 2014-11-10 | 2016-01-13 | 四川大学 | 一种纤维增强型载药水凝胶人工角膜裙边支架及其制备方法 |
| AU2015360469B2 (en) * | 2014-12-10 | 2021-03-25 | Incept, Llc | Hydrogel drug delivery implants |
| CN104587531B (zh) * | 2014-12-25 | 2016-05-04 | 南京臻泉医药科技有限公司 | 一种修复关节软骨损伤的凝胶支架的制备方法 |
| US20160303281A1 (en) * | 2015-04-17 | 2016-10-20 | Rochal Industries, Llc | Composition and kits for pseudoplastic microgel matrices |
| EP3291886A1 (en) | 2015-05-04 | 2018-03-14 | Ecole Polytechnique Federale de Lausanne (EPFL) | Ophthalmic contact lens with a compressible affinity matrix |
| KR102643821B1 (ko) | 2015-06-06 | 2024-03-07 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
| TWI700085B (zh) | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
| CN105169476B (zh) * | 2015-09-15 | 2018-06-22 | 王岩松 | 一种医用原位凝胶的制备方法及其应用 |
| WO2017053686A1 (en) * | 2015-09-24 | 2017-03-30 | Massachusetts Eye And Ear Infirmary | Drug delivery system and methods of use |
| PL3352766T3 (pl) | 2015-09-24 | 2021-08-02 | Matrix Biology Institute | Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia |
| CN106692977A (zh) * | 2015-11-11 | 2017-05-24 | 陶虎 | 一种蚕丝蛋白胶囊及其制备方法 |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN108778330A (zh) * | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| WO2017165449A1 (en) * | 2016-03-22 | 2017-09-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular biologic delivery |
| KR20190008210A (ko) | 2016-04-08 | 2019-01-23 | 코넬 유니버시티 | 실크 유래 단백질을 이용한 상처 치료를 증가시키는 방법 |
| ES2972417T3 (es) | 2016-05-18 | 2024-06-12 | Sonikure Holdings Ltd | Sistema de administración transescleral de fármacos mejorada por ultrasonidos |
| KR102657707B1 (ko) | 2016-06-02 | 2024-04-15 | 에이디에스 테라퓨틱스 엘엘씨 | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 |
| US11395853B2 (en) | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
| US11278546B2 (en) * | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
| MX2019001633A (es) | 2016-08-12 | 2019-09-18 | Silk Tech Ltd | Proteina derivada de la seda para el tratamiento de la inflamacion. |
| CN109890964A (zh) * | 2016-09-09 | 2019-06-14 | 康奈尔大学 | 核酸、蛋白和小分子在玻璃体囊泡体中的递送 |
| PT3513809T (pt) | 2016-09-13 | 2022-05-02 | Kyowa Kirin Co Ltd | Composição medicinal compreendendo tivozanib |
| WO2019055594A1 (en) | 2017-09-13 | 2019-03-21 | North Carolina State University | BRUSHING ADIPOSE TISSUE INDUCED LOCALLY BY MICRO-NEEDLE STAMPS FOR THE TREATMENT OF OBESITY |
| WO2019094702A1 (en) * | 2017-11-10 | 2019-05-16 | Cocoon Biotech Inc. | Ocular applications of silk-based products |
| CN108079431A (zh) * | 2018-02-12 | 2018-05-29 | 南通纺织丝绸产业技术研究院 | 一种多层丝素蛋白复合针壁微针 |
| CN108310618A (zh) * | 2018-02-12 | 2018-07-24 | 南通纺织丝绸产业技术研究院 | 一种多层复合针壁丝素蛋白微针及其制备方法 |
| CN108392728A (zh) * | 2018-02-12 | 2018-08-14 | 南通纺织丝绸产业技术研究院 | 一种丝素蛋白多层复合微针及其制备方法 |
| KR102810631B1 (ko) * | 2018-02-26 | 2025-05-23 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 약물 전달 시스템 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| BR112020020930A2 (pt) | 2018-04-11 | 2021-03-02 | Ohio State Innovation Foundation | composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit |
| US20200085979A1 (en) * | 2018-09-11 | 2020-03-19 | Stanley Satz | Precision medicine theranostics and diagnostics a combination thereof |
| AU2019343188A1 (en) | 2018-09-21 | 2021-05-20 | Aufbau Medical Innovations Limited | Compositions and methods for glaucoma |
| WO2020102810A1 (en) | 2018-11-16 | 2020-05-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive gel eye drop for ocular delivery of cysteamine |
| AU2020219436A1 (en) * | 2019-02-08 | 2021-10-07 | Ohio State Innovation Foundation | Drug delivery compositions for ocular administration of therapeutics and methods of use thereof |
| MX2021010599A (es) * | 2019-03-05 | 2021-12-10 | Aerie Pharmaceuticals Inc | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. |
| EP3976106A4 (en) | 2019-05-31 | 2023-01-11 | DOSE Medical Corporation | BIOERODABLE POLYESTER-POLYMER IMPLANTS AND ASSOCIATED METHODS OF USE |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20210127976A1 (en) * | 2019-11-01 | 2021-05-06 | Koninklijke Philips N.V. | System and method for assessing preparedness for imaging procedures |
| EP4057941A4 (en) * | 2019-11-15 | 2024-05-29 | Silk Technologies Ltd. | Stable formulations of silk-derived protein |
| EP3884929B1 (en) * | 2020-03-25 | 2023-06-14 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| WO2021205471A1 (en) * | 2020-04-06 | 2021-10-14 | Jawaharlal Nehru Centre For Advanced Scientific Research | Composition, injectable hydrogel and methods thereof |
| CN113440604B (zh) * | 2021-06-24 | 2022-05-31 | 浙江泽瑞生物医药有限公司 | 一种有效抑制血糖的索马鲁肽的口服缓释片剂及其制备方法 |
| US20240366565A1 (en) * | 2021-09-09 | 2024-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury |
| JP2025519378A (ja) | 2022-06-07 | 2025-06-26 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 視覚回復のためのメラノプシンバリアント |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN120897764A (zh) | 2023-04-11 | 2025-11-04 | 视尔普斯眼科公司 | 包含阿西替尼多晶型物iv的眼部植入物 |
| CN116687840B (zh) * | 2023-08-03 | 2023-10-20 | 四川省医学科学院·四川省人民医院 | 一种用于治疗眼部病状的凝胶制剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1505542A1 (ru) * | 1988-01-13 | 1989-09-07 | А. И. Иголкин | Медицинска пипетка А.И.Иголкина дл глазных капель |
| AUPQ496500A0 (en) * | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| US20070026043A1 (en) * | 2003-11-20 | 2007-02-01 | Angiotech International Ag | Medical devices combined with diblock copolymer compositions |
| WO2006078282A2 (en) * | 2004-04-28 | 2006-07-27 | Angiotech Biomaterials Corporation | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| US8178656B2 (en) * | 2004-06-11 | 2012-05-15 | Trustees Of Tufts College | Silk-based drug delivery system |
| PT2029746E (pt) * | 2006-06-12 | 2012-10-15 | Exegenics Inc D B A Opko Health Inc | Composições e métodos para a inibição do sirna de angiogenese |
| KR20100029217A (ko) * | 2007-05-29 | 2010-03-16 | 트러스티즈 오브 터프츠 칼리지 | 음파 처리를 이용한 실크 피브로인 겔화 방법 |
| US20110206773A1 (en) * | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
| EP2421551B2 (en) * | 2009-04-20 | 2020-07-15 | Allergan, Inc. | Silk fibroin hydrogels and uses thereof |
| US20110111031A1 (en) * | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
| US9603971B2 (en) * | 2010-03-05 | 2017-03-28 | Trustees Of Tufts College | Silk-based ionomeric compositions |
| EP2558103A4 (en) * | 2010-04-12 | 2013-09-25 | R Tech Ueno Ltd | PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM |
-
2013
- 2013-02-22 US US14/380,333 patent/US20150037422A1/en not_active Abandoned
- 2013-02-22 EP EP13752210.8A patent/EP2817031A4/en not_active Withdrawn
- 2013-02-22 HK HK15106047.3A patent/HK1205461A1/xx unknown
- 2013-02-22 JP JP2014558897A patent/JP2015508104A/ja active Pending
- 2013-02-22 CA CA2865132A patent/CA2865132A1/en not_active Abandoned
- 2013-02-22 WO PCT/US2013/027465 patent/WO2013126799A1/en not_active Ceased
-
2016
- 2016-09-28 US US15/279,186 patent/US20170173161A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508104A5 (https=) | ||
| US20170173161A1 (en) | Compositions and methods for ocular delivery of a therapeutic agent | |
| JP6132964B2 (ja) | 萎縮性加齢性黄斑変性の処置方法 | |
| Liu et al. | Characterization of biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of ranibizumab | |
| US12357564B2 (en) | Methods and compositions for sustained release microparticles for ocular drug delivery | |
| JP7636334B2 (ja) | 治療物質の眼投与のための薬物送達組成物及びその使用法 | |
| CA2901280A1 (en) | Sustained drug delivery implant | |
| JP2018532563A (ja) | 眼科用組成物 | |
| Robert et al. | A drug delivery system for administration of anti–TNF-α antibody | |
| Heljak et al. | Investigating bevacizumab and its fragments sustained release from intravitreal administrated PLGA microspheres: a modeling approach | |
| KR20190110101A (ko) | 안구내 약물 전달 장치 및 관련 방법들 | |
| Robert et al. | A Drug Delivery System for Administration of Anti–TNF-a Antibody | |
| HK40012677A (en) | Treating atrophic age related macular degeneration | |
| AU2013245543A1 (en) | Intraocular drug delivery device and associated methods | |
| HK1190092A (en) | Bevacizumab for use in a method for treating atrophic age related macular degeneration |